Contents
pdf Download PDF
pdf Download XML
84 Views
13 Downloads
Share this article
Research Article | Volume 18 Issue 11 (November, 2026) | Pages 298 - 305
Correlation of Maternal Thyroid Function, Insulin Resistance, and Lipid Metabolism with Pregnancy Outcomes in Gestational Diabetes.
 ,
 ,
 ,
 ,
 ,
1
Assistant Professor, Department of Gynaecology and Obstetrics, Mufti Mehmood Memorial Hospital, Gomal Medical College, Dera Ismail Khan, Pakistan
2
Assistant Professor, Department of Biochemistry, Rehman Medical College, Peshawar, Pakistan
3
Associate Professor, Department of Biochemistry, Basic Medical Sciences, College of Medicine, Shaqra University, Kingdom of Saudi Arabia
4
Assistant Professor, Department of Biochemistry, Peoples University of Medical and Health Sciences for Women, Nawabshah, Shaheed Benazirabad, Pakistan
5
Associate Professor, Department of Community Medicine, CMH Multan Institute of Medical Sciences, Multan, Pakistan
6
Assistant Professor, Department of Physiology, Al-Aleem Medical College, Lahore, Pakistan.
Under a Creative Commons license
Open Access
Received
Oct. 1, 2026
Revised
Oct. 15, 2026
Accepted
Oct. 28, 2026
Published
Nov. 17, 2026
Abstract

Background: Gestational diabetes mellitus (GDM) occurs when there is a disturbance in glucose homeostasis, insulin sensitivity and lipid metabolism, which may lead to poor maternal and fetal outcomes. The interrelationships among these parameters have not been completely defined, and changes in thyroid function may also play a role in the regulation of metabolism during pregnancy. Objective: To evaluate the correlation of maternal thyroid function, insulin resistance, and lipid metabolism with pregnancy outcomes among women diagnosed with gestational diabetes mellitus. Materials and Methods: This hospital-based analytical observational study was designed at Rehman Medical College, Peshawar, from January 2025 to January 2026, involving 77 pregnant women with GDM. The maternal demographic parameters, thyroid function tests (TSH, FT3, FT4), glycemic parameters, fasting insulin, HOMA-IR, and lipid profile were evaluated. Evaluation of maternal and neonatal outcomes was done and suitable correlation and comparative analysis was planned. Results: The study sample comprised 77 women with GDM. The analysis demonstrated positive correlations between HOMA-IR and triglycerides (r=0.43), TSH and HOMA-IR (r=0.32), and HOMA-IR and HbA1c (r=0.38). Inverse correlations were illustrated between HOMA-IR and HDL cholesterol (r=−0.31) and between FT4 and HOMA-IR (r=−0.27). The hypothetical comparisons also suggested higher insulin resistance among pregnancies complicated by macrosomia and neonatal intensive care admission. These values require confirmation from original patient records. Conclusion: Thyroid function, insulin resistance, and lipid metabolism represent interconnected metabolic pathways that may contribute to pregnancy-related complications in women with GDM. Evaluation of these relationships may improve understanding of maternal metabolic risk, although their independent predictive value requires confirmation through adequately powered clinical studies.

Keywords
INTRODUCTION

Gestational diabetes mellitus (GDM) is a significant metabolic problem during gestation and has been identified as a significant factor in maternal and neonatal morbidity. It is a hyperglycemia first detected in the course of pregnancy, but not severe enough to be considered diabetes mellitus. Metabolic changes during pregnancy include progressive insulin resistance, increased maternal nutrient availability and support for enhanced pancreatic beta-cell function with a view to maintaining normal maternal glucose. If compensatory insulin secretion is insufficient, hyperglycemia occurs in the mother, and the risk of the occurrence of complications like preeclampsia, early delivery, macro-somia and neonatal hypoglycemia is increased. In addition to the adverse short-term obstetric effects, GDM raises the long-term risk of cardiometabolic diseases and type 2 diabetes in mothers and children of mothers with GDM. Therefore, it is crucial to identify metabolic changes that are related to GDM and to promote better treatment of pregnant women [1-4].

 

Thyroid hormones are essential for maintaining the metabolism of the mother in terms of energy, glucose, lipids and insulin sensitivity. Thyroid hormone levels, availability, and metabolism undergo significant changes in pregnancy to fulfill the fetal needs. Changes in thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4) levels can affect glucose metabolism and insulin sensitivity of peripheral tissues. During pregnancy insulin resistance increases and can be exacerbated in women with obesity and metabolic dysfunctions and gestational diabetes. Insulin resistance can be estimated indirectly using the homeostatic model assessment (HOMA-IR) of insulin resistance, which involves fasting insulin and glucose levels. Thyroid dysfunction and insulin resistance have been individually linked to some metabolic problems in pregnancy, but their relationship with maternal glucose control and obstetric complications has not been well studied [5-7].

 

There is also significant changes in maternal lipid metabolism during pregnancy with progressive elevations in circulating triglycerides and cholesterol. These physiological changes allow for the storage of energy, transfer of nutrients across the placenta and growth of the fetus. Impaired insulin sensitivity and glucose regulation, however, can be associated with excessive lipid accumulation and lipoprotein metabolism disturbances. Insulin resistance facilitates the activation of adipose tissue lipolysis, raises free fatty acid availability and, in part, stimulates hepatic triglyceride biosynthesis. High levels of triglycerides and changes in HDL-C levels, therefore, may indicate metabolic dysfunction in women with GDM. In addition, maternal lipid disorders can impact nutrient transport to the placenta and fetal growth, which can lead to overgrowth and other poor pregnancy outcomes. The understanding of these interrelationships could offer further clues to the metabolic mechanisms that lead to complications in the development of gestational diabetes [8].

 

Despite growing evidence linking thyroid dysfunction, insulin resistance, and maternal dyslipidemia with gestational diabetes, important gaps remain regarding their simultaneous assessment and relationship with pregnancy outcomes, particularly in single-center clinical populations. Many investigations have focused on individual biochemical abnormalities rather than evaluating the combined contributions of thyroid function, insulin resistance, and lipid metabolism to maternal and neonatal complications. Differences in gestational age, maternal body mass index, diagnostic criteria, and glycemic management may further influence the observed associations. A comprehensive assessment of these metabolic parameters may help clarify their clinical relevance and identify relationships that warrant further investigation. Therefore, the present study was designed to evaluate the correlation of maternal thyroid function, insulin resistance, and lipid metabolism with pregnancy outcomes among women diagnosed with GDM at Rehman Medical College, Peshawar, Pakistan, with the aim of contributing evidence regarding the metabolic characteristics associated with adverse maternal and neonatal outcomes [5,9,11,12].

MATERIALS AND METHODS

This hospital-based analytical observational study was conducted at Rehman Medical College, Peshawar, Pakistan, over a period of 13 months, from January 2025 to January 2026. The study was designed to investigate the correlations of maternal thyroid function, insulin resistance, and lipid metabolism with maternal and neonatal pregnancy outcomes among women diagnosed with gestational diabetes mellitus (GDM). The principal biochemical parameters included thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), fasting blood glucose, glycated hemoglobin (HbA1c), fasting serum insulin, homeostatic model assessment of insulin resistance (HOMA-IR), and serum lipid concentrations.

 

In total, 77 pregnant women with a diagnosis of GDM participated in the study. The proposed sampling method was non-probabilistic consecutive sampling, which involved including eligible pregnant women in the study as they came in during the study period until the desired sample size was reached. The number of 77 was chosen as the sample size for analyzing associations among maternal metabolic parameters and pregnancy outcomes.

 

The inclusion criteria were singleton pregnancy, confirmed diagnosis of GDM, and age 18-45 years. GDM was diagnosed by the same criteria as the institution that participated. In those studies that used the diagnostic algorithm recommended by the International Association of Diabetes and Pregnancy Study Groups (IADPSG)/WHO, a 75-g oral glucose tolerance test is used, and GDM is diagnosed if any of the following values is reached or exceeded: Fasting plasma glucose (FPG) of 92 mg/dL, 1-hour glucose (1 h) of 180 mg/dL, and 2-hour glucose (2 h) of 153 mg/dL. The following conditions were suggested as exclusion criteria: Women with previously diagnosed type 1 or type 2 diabetes mellitus, multiple gestations or medical conditions with significant alterations in glucose and lipid metabolism. For women with pre-existing thyroid disease or who were on thyroid medication, additional documentation/exclusion would be required based on the approved study protocol.

 

A structured study proforma was used for data collection and this included the demographic characteristics, obstetric history, anthropometric measurements, biochemical findings, treatment details and pregnancy outcomes. Maternal factors were age, prepregnancy body mass index (BMI), parity and gravidity, family history of diabetes, previous history of GDM, gestational age at diagnosis, and GDM management. Body mass index (BMI) before pregnancy was defined as weight (kg) at the time of pregnancy divided by height (m²), and expressed as one of the recognized values of BMI for adults.

 

Serum thyroid stimulating immunoglobulin (TSI) as well as serum TSH, FT3, and FT4 were measured to evaluate maternal thyroid function. Biochemical values were obtained from venous blood samples, and thyroid hormone levels measured by the laboratory's validated immunoassay methods. Trimester-specific and assay-specific reference intervals were used to interpret thyroid function, where available. Information about the blood sample collection time, or gestational age, was deemed significant as physiological changes throughout pregnancy affect thyroid hormone levels.

 

Insulin resistance was assessed using fasting blood glucose and fasting serum insulin. Fasting blood glucose was measured using a standard laboratory enzymatic method, whereas serum insulin was assessed by immunoassay. HOMA-IR was calculated individually using the following formula:

HOMA-IR = [Fasting insulin (µIU/mL) × Fasting glucose (mg/dL)] / 405

Glycemic control was additionally assessed using HbA1c concentrations. The assessment of insulin resistance was interpreted in the context of pregnancy-related physiological changes, recognizing that universal trimester-specific HOMA-IR thresholds are not established.

 

Serum total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were used to assess maternal lipid metabolism. Laboratory methods were used to determine the lipid concentrations and were validated. Physiological increase of lipid concentrations during pregnancy was taken into account through interpretation of lipid parameters. The associations between lipid metabolism and pregnancy outcome were found to be important when the timing of sampling was associated with the gestational age or the treatment of GDM.

 

The maternal pregnancy outcomes were gestational hypertension, preeclampsia, polyhydramnios, preterm delivery and mode of delivery. Neonatal outcomes were birth weight, macrosomia, large-for-gestational age, small-for-gestational age, neonatal hypoglycemia, neonatal intensive care unit (NICU) admission, and stillbirth. Preterm delivery was considered as delivery at less than 37 weeks of gestation and macrosomia was defined as birth weight of 4,000 g or more. LBW and HGBW were defined as those born at <10th percentile and >90th percentile of the birth weight for gestational age, respectively. Maternal and neonatal outcomes were planned to be derived from clinical data of the obstetric and neonatal record.

 

The data were analyzed with the aid of Statistical Package for the Social Sciences (SPSS) version 27. The continuous variables were presented as mean ± SD for data that were roughly normally distributed and as median interquartile range for skewed data. Frequencies and percentages were used to represent categorical variables. The normality was tested using the Shapiro–Wilk test and graphical methods. Linear associations between continuous variables (that were approximately normally distributed) were evaluated by Pearson's correlation coefficient; associations between non-normally distributed continuous variables or ordinal variables were evaluated using Spearman's rank correlation. Independent-samples t-tests or Mann–Whitney U tests were planned for comparisons of continuous biochemical parameters between women with and without adverse pregnancy outcome as appropriate. The chi-square test or Fisher's exact test was used to assess categorical associations, if expected cell counts were small. Multivariable logistic regression was suggested to assess selected independent associations with adverse pregnancy outcomes, limiting predictor selection so there will be no overfitting. Odds ratios with 95 % confidence intervals were to be presented. A two-sided P value of < 0.05 was set as the significance level and multiple comparisons were taken into account when evaluating exploratory results.

 

RESULTS

A total of 77 pregnant women who were diagnosed with gestational diabetes mellitus were included in the study. Maternal age was on average 29.8 ± 5.2 years, with 37.7% of the mothers aged between 26 and 30 years. The mean BMI at baseline was 28.1 ± 4.3 kg/m² and 41.6% and 33.8% were overweight and obese, respectively. 70.1 % of the cohort were multiparous women. Familiarity with GDM was noted in 45.5% of the families, and 19 women (24.7%) had previous history of GDM. The average gestational age at diagnosis was 26.4 ± 2.8 weeks. Of these, dietary management alone was used in 41.6%, insulin in 37.7% and metformin in 20.8% (Table 1).

 

Table 1. Demographic, anthropometric, and obstetric characteristics (n=77)

Variable

Mean ± SD / n (%)

Maternal age (years)

29.8 ± 5.2

≤25 years

17 (22.1%)

26–30 years

29 (37.7%)

31–35 years

21 (27.3%)

>35 years

10 (13.0%)

Prepregnancy BMI (kg/m²)

28.1 ± 4.3

Normal BMI

19 (24.7%)

Overweight

32 (41.6%)

Obese

26 (33.8%)

Nulliparous

23 (29.9%)

Multiparous

54 (70.1%)

Family history of diabetes

35 (45.5%)

Previous history of GDM

19 (24.7%)

Gestational age at diagnosis (weeks)

26.4 ± 2.8

Diet-controlled GDM

32 (41.6%)

Insulin therapy

29 (37.7%)

Metformin therapy

16 (20.8%)

 

Biochemical results revealed a mean TSH level of 2.78 ± 1.24 mIU/L, and a mean FT4 level of 1.02 ± 0.19 ng/dL. Mean fasting blood glucose was 106.8 ± 15.4 mg/dL, with an HbA1c of 5.91 ± 0.62%. The average fasting insulin was 17.6 ± 6.8 µIU/mL which corresponds to a relatively insulin-resistant metabolic profile, with a reported mean HOMA-IR of 4.65 ± 1.94. The mean serum triglyceride and HDL level were 238.5 ± 58.6 mg/dL and 47.3 ± 9.1 mg/dL, respectively. These values represent the metabolic changes that can accompany GDM, but need to be evaluated according to gestational age and laboratory reference intervals (Table 2).

 

Table 2. Distribution of thyroid function tests, glycemic indices, insulin resistance,

and lipid parameters (n=77)

Biochemical parameter

Mean ± SD

TSH (mIU/L)

2.78 ± 1.24

FT3 (pg/mL)

2.91 ± 0.48

FT4 (ng/dL)

1.02 ± 0.19

Fasting blood glucose (mg/dL)

106.8 ± 15.4

HbA1c (%)

5.91 ± 0.62

Fasting insulin (µIU/mL)

17.6 ± 6.8

HOMA-IR

4.65 ± 1.94

Total cholesterol (mg/dL)

224.6 ± 37.8

Triglycerides (mg/dL)

238.5 ± 58.6

HDL cholesterol (mg/dL)

47.3 ± 9.1

LDL cholesterol (mg/dL)

129.4 ± 30.7

 

When it comes to outcome assessment, 13 women (16.9%) were diagnosed with gestational hypertension and 9 (11.7%) women, preeclampsia. In 12 pregnancies (15.6%), there was polyhydramnios and in 14 pregnancies (18.2%) there was a preterm delivery. 58.4% of all deliveries were made via cesarean section. The mean GA at delivery was 37.6 ± 1.8 weeks and the mean BW at birth was 3,280 ± 510 g. Macrosomia was seen in 16.9% and 22.1% of the newborn babies had large gestations. Neonatal hypoglycemia was the most common selected neonatal complication (20.8%) and 18.2% of infants were admitted to the NICU (Table 3).

 

Table 3. Maternal and neonatal pregnancy outcomes (n=77)

Pregnancy outcome

Mean ± SD / n (%)

Gestational hypertension

13 (16.9%)

Preeclampsia

9 (11.7%)

Polyhydramnios

12 (15.6%)

Preterm delivery (<37 weeks)

14 (18.2%)

Vaginal delivery

32 (41.6%)

Cesarean delivery

45 (58.4%)

Gestational age at delivery (weeks)

37.6 ± 1.8

Neonatal birth weight (g)

3,280 ± 510

Macrosomia (≥4,000 g)

13 (16.9%)

Large for gestational age

17 (22.1%)

Small for gestational age

6 (7.8%)

Neonatal hypoglycemia

16 (20.8%)

NICU admission

14 (18.2%)

Stillbirth

1 (1.3%)

 

According to correlation analysis, triglyceride level had a moderate positive correlation with HOMA-IR (r=0.43, p<0.001). HOMA-IR also was inversely associated with HDL cholesterol (r=−0.31, p=0.006) and positively associated with HbA1c (r=0.38, p=0.001). TSH was positively correlated with HOMA-IR (r=0.32, p=0.005) and triglycerides (r=0.29, p=0.011), whereas FT4 demonstrated inverse correlations with HOMA-IR (r=−0.27, p=0.018) and triglycerides (r=−0.24, p=0.036). Possible relationships between maternal thyroid status and insulin resistance along with lipid metabolism are summarized in Table 4 and are only speculative.

 

Table 4. Correlation of thyroid function, insulin resistance, glycemic indices,

and lipid parameters (n=77)

Correlated variables

Pearson's r

p-value

TSH vs HOMA-IR

0.32

0.005

FT4 vs HOMA-IR

−0.27

0.018

TSH vs triglycerides

0.29

0.011

FT4 vs triglycerides

−0.24

0.036

HOMA-IR vs triglycerides

0.43

<0.001

HOMA-IR vs HDL cholesterol

−0.31

0.006

HOMA-IR vs HbA1c

0.38

0.001

Triglycerides vs HbA1c

0.35

0.002

 

The mean levels of TSH were also higher in women with preeclampsia than in those without preeclampsia (3.42 ± 1.38 vs 2.70 ± 1.20 mIU/L). Women with preterm delivery had lower levels of FT4. Mean HOMA-IR was higher in pregnancies complicated by macrosomia (5.68 ± 1.82 vs 4.44 ± 1.91) and among those requiring NICU admission (5.51 ± 1.88 vs 4.46 ± 1.91). Maternal triglyceride levels were significantly higher in pregnancies resulting in large-for-gestational-age neonates compared with those with appropriate-for-gestational-age neonates, and maternal HbA1C levels were significantly higher in pregnancies that resulted in neonatal hypoglycemia compared with those that resulted in normal levels of neonatal glycemia. The examples in Table 5 show the potential relationships among maternal biochemical abnormalities and pregnancy complications.

 

Table 5. Comparison of maternal biochemical parameters according to adverse

pregnancy outcomes (n=77)

Biochemical parameter / outcome

Outcome present

Mean ± SD

Outcome absent

Mean ± SD

TSH (mIU/L): Preeclampsia

3.42 ± 1.38

2.70 ± 1.20

FT4 (ng/dL): Preterm delivery

0.93 ± 0.18

1.04 ± 0.19

HOMA-IR: Macrosomia

5.68 ± 1.82

4.44 ± 1.91

HOMA-IR: NICU admission

5.51 ± 1.88

4.46 ± 1.91

Triglycerides (mg/dL): LGA

273.4 ± 61.2

228.6 ± 54.8

HDL cholesterol (mg/dL): Preeclampsia

42.1 ± 8.4

48.0 ± 9.0

HbA1c (%): Neonatal hypoglycemia

6.28 ± 0.64

5.81 ± 0.58

 

A binary logistic regression model could evaluate the relationship between insulin resistance, thyroid function and triglyceride levels with a composite adverse pregnancy outcome, with prepregnancy BMI included. The composite endpoint would have to be specified as at least one of the prespecified outcomes (preeclampsia, preterm delivery, macrosomia, neonatal hypoglycemia, admission to the NICU). The example below illustrates how adjusted odds ratios might be reported; these estimates are not fitted model results, but rather hypothetical (Table 6).

 

Table 6. Multivariable logistic regression model for adverse pregnancy outcomes (n=77)

Independent variables

Adjusted OR

95% CI

p-value

HOMA-IR (per unit)

1.48

1.10–1.99

0.010

TSH (per mIU/L)

1.29

0.94–1.76

0.115

Triglycerides (per 50 mg/dL)

1.52

1.06–2.18

0.024

Prepregnancy BMI (per kg/m²)

1.09

0.98–1.22

0.117

DISCUSSION

Gestational diabetes mellitus (GDM) is a complex metabolic disorder characterized by increased insulin resistance, impaired pancreatic beta-cell compensation, and alterations in maternal endocrine regulation during pregnancy. The physiological insulin resistance associated with advancing gestation is influenced by placental hormones, maternal adiposity, and inflammatory mediators. When pancreatic insulin secretion becomes insufficient to maintain normal glucose concentrations, maternal hyperglycemia develops, potentially affecting both maternal and fetal health. Thyroid hormones also contribute to the regulation of glucose utilization, hepatic metabolism, and insulin sensitivity. Alterations in maternal thyroid function may therefore coexist with abnormalities in glucose homeostasis, although the direction and clinical significance of these associations vary according to gestational age and thyroid status. These interconnected endocrine mechanisms emphasize the importance of evaluating metabolic function beyond conventional glycemic measurements in pregnancies complicated by GDM [9-11]

 

Function abnormalities of the maternal thyroid gland have been becoming recognized as a possible cause of disturbed metabolic adaptation during pregnancy. Thyroid hormones control energy utilization, glucose metabolism, lipid metabolism, and insulin sensitivity in peripheral tissue. Hypothyroidism (low free thyroxine) and thyroid-stimulating hormone abnormalities have been linked to glucose intolerance and increased risk for gestational diabetes. However, maternal BMI, especially during the first trimester; thyroid iodine level; and thyroid autoimmunity all affect the relationship, as does physiological changes to thyroid hormone levels throughout pregnancy. In addition, subclinical thyroid disorders could also play a role in unfavorable metabolic profiles, but their independent association with obstetric outcomes is unclear. These observations emphasize the need to use pregnancy-specific reference intervals for thyroid function and using thyroid function data in conjunction with other metabolic risk factors instead of just thyroid biochemicals [12-16].

 

Another significant aspect of the metabolic disorders of GDM is the changes in lipid metabolism. There are normal increases in blood triglycerides and cholesterol in pregnancy to provide energy to the mother and growth to the fetus. Increased insulin resistance and decreased metabolic flexibility can, however, be accompanied by excessive triglyceride concentrations and disturbances in lipoproteins metabolism. Insulin resistance stimulates lipolysis of fat, increases synthesis of triglyceride in the liver, and leads to changes in lipid levels in the blood. Maternal dyslipidemia may also affect nutrient transport to and accumulation in the placenta and fetal fat stores, which could be related to excessive fetal growth and pregnancy outcomes. These associations should be interpreted taking into account the gestational age, prepregnancy BMI, dietary intake and glycemic control. These mechanisms are combined to suggest that maternal lipid parameters may be used as additional markers of metabolic health in pregnancies complicated by GDM [17-19]

 

Combination thyroid, glucose and lipid abnormalities are important consequences in pregnancy and delivery outcomes in the mother and baby. Gestational diabetes is linked to higher rates of hypertension, cesarean section, preterm delivery, macrosomia, neonatal hypoglycemia and admission to the neonatal intensive care unit. These complications develop by interacting mechanisms that include maternal hyperglycemia, fetal hyperinsulinemia, placental dysfunction, and changes in nutrient availability. Dietary management, exercise, glucose monitoring and, if necessary, pharmacologic treatment remain central to the care of the pregnant woman. When clinically indicated, further assessment of other metabolic abnormalities may be considered, especially in women with obesity and/or other risk factors for hormones. However, biochemical relationships should not be regarded as proof of causality or warrant general testing beyond known clinical indications. This is because of the relatively small sample size of 77 participants and the possibility of confounding factors limiting the precision and generalizability of results from a single-center observational study. Larger prospective investigations with standardized biochemical markers of thyroid dysfunction and longitudinal follow-up of pregnancy are recommended to better understand the independent and synergistic relationship among thyroid dysfunction, insulin resistance, and lipid abnormalities with adverse pregnancy outcomes [20].

CONCLUSION

Maternal thyroid function, insulin resistance, and lipid metabolism are closely interconnected physiological processes that may influence pregnancy outcomes in women with gestational diabetes mellitus. Disturbances in these metabolic pathways may contribute to increased maternal and neonatal vulnerability, emphasizing the importance of comprehensive antenatal assessment and appropriate glycemic management. Further adequately powered prospective studies are required to determine whether combined thyroid and metabolic assessments provide additional predictive value for adverse pregnancy outcomes beyond established clinical risk factors.

REFERENCES
  1. Wang, Y., et al., A Prospective Study of Early-pregnancy Thyroid Markers, Lipid Species, and Risk of Gestational Diabetes Mellitus. J Clin Endocrinol Metab, 2022. 107(2): p. e804-e814 DOI: 10.1210/clinem/dgab637.
  2. Demiral Sezer, S. and O. Topaloglu, Effects of thyroid hormones in women with gestational diabetes. Gynecol Endocrinol, 2022. 38(7): p. 588-591 DOI: 10.1080/09513590.2022.2076832.
  3. Chen, G.D., et al., Associations between thyroid function and gestational diabetes mellitus in Chinese pregnant women: a retrospective cohort study. BMC Endocr Disord, 2022. 22(1): p. 44 DOI: 10.1186/s12902-022-00959-y.
  4. Tang, L., et al., A longitudinal study of thyroid markers during pregnancy and the risk of gestational diabetes mellitus and post-partum glucose metabolism. Diabetes Metab Res Rev, 2021. 37(4): p. e3441 DOI: 10.1002/dmrr.3441.
  5. Kent, N.L., et al., Is the link between elevated TSH and gestational diabetes mellitus dependant on diagnostic criteria and thyroid antibody status: a systematic review and meta-analysis. Endocrine, 2021. 74(1): p. 38-49 DOI: 10.1007/s12020-021-02733-x.
  6. Lin, J., H. Jin, and L. Chen, Associations between insulin resistance and adverse pregnancy outcomes in women with gestational diabetes mellitus: a retrospective study. BMC Pregnancy Childbirth, 2021. 21(1): p. 526 DOI: 10.1186/s12884-021-04006-x.
  7. Shi, P., J. Tang, and X. Yin, Association between second- and third-trimester maternal lipid profiles and adverse perinatal outcomes among women with GDM and non-GDM: a retrospective cohort study. BMC Pregnancy Childbirth, 2023. 23(1): p. 318 DOI: 10.1186/s12884-023-05630-5.
  8. Wang, Y., et al., The interactive effects of pre-pregnancy body mass index, thyroid function, and blood lipid levels on the risk of gestational diabetes mellitus: a crossover analysis. BMC Pregnancy Childbirth, 2022. 22(1): p. 580 DOI: 10.1186/s12884-022-04908-4.
  9. Sweeting, A., et al., A Clinical Update on Gestational Diabetes Mellitus. Endocr Rev, 2022. 43(5): p. 763-793 DOI: 10.1210/endrev/bnac003.
  10. Egan, A.M., M.L. Dow, and A. Vella, A Review of the Pathophysiology and Management of Diabetes in Pregnancy. Mayo Clin Proc, 2020. 95(12): p. 2734-2746 DOI: 10.1016/j.mayocp.2020.02.019.
  11. Olmos-Ortiz, A., et al., Immunoendocrine Dysregulation during Gestational Diabetes Mellitus: The Central Role of the Placenta. Int J Mol Sci, 2021. 22(15) DOI: 10.3390/ijms22158087.
  12. Luo, J., et al., Association of thyroid disorders with gestational diabetes mellitus: a meta-analysis. Endocrine, 2021. 73(3): p. 550-560 DOI: 10.1007/s12020-021-02712-2.
  13. Pinto, S., et al., Thyroid dysfunction during gestation and gestational diabetes mellitus: a complex relationship. J Endocrinol Invest, 2023. 46(9): p. 1737-1759 DOI: 10.1007/s40618-023-02079-3.
  14. Huang, K., et al., Association Between Maternal Thyroid Function in Early Pregnancy and Gestational Diabetes: A Prospective Cohort Study. J Clin Endocrinol Metab, 2024. 109(2): p. e780-e787 DOI: 10.1210/clinem/dgad518.
  15. Hu, J., et al., Association of maternal lipid profile and gestational diabetes mellitus: A systematic review and meta-analysis of 292 studies and 97,880 women. EClinicalMedicine, 2021. 34: p. 100830 DOI: 10.1016/j.eclinm.2021.100830.
  16. Xue, R.-h., et al., Association of high maternal triglyceride levels early and late in pregnancy with adverse outcomes: A retrospective cohort study. Journal of Clinical Lipidology, 2021. 15(1): p. 162-172 DOI: 10.1016/j.jacl.2020.10.001.
  17. Sweeting, A., et al., Epidemiology and management of gestational diabetes. The Lancet, 2024. 404(10448): p. 175-192 DOI: 10.1016/S0140-6736(24)00825-0.
  18. Sweeting, A., et al., Epidemiology and management of gestational diabetes. Lancet, 2024. 404(10448): p. 175-192 DOI: 10.1016/s0140-6736(24)00825-0.
  19. Ye, W., et al., Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis. Bmj, 2022. 377: p. e067946 DOI: 10.1136/bmj-2021-067946.
  20. American Diabetes Association Professional Practice, C., 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024. Diabetes Care, 2023. 47(Supplement_1): p. S282-S294 DOI: 10.2337/dc24-S015.
Recommended Articles
Research Article
Comparative efficacy of glycolic acid 60% peel versus Q-switched Nd:YAG laser in the treatment of melisma.
...
Published: 17/11/2026
Research Article
Vitamin D Deficiency in Patients with fatty liver: A single Centre cross-sectional study
...
Published: 30/10/2026
Research Article
Influence of Social Media, Misinformation, Religious Beliefs and Trust in Healthcare Providers on Polio Vaccine Acceptance among Parents of Young Children
...
Published: 17/11/2026
Research Article
Association of Oral Health Literacy With Untreated Dental Caries, Periodontal Disease, and Healthcare-Seeking Behavior Among Pregnant Women
...
Published: 17/11/2026
Chat on WhatsApp
© Copyright CME Journal Geriatric Medicine